blog navigation

blog posts

  • Study: Drugs reprogram genes in breast tumors to prevent endocrine resistance

    Group photo of Zeynep Madak-Erdogan's team

    Targeting estrogen receptor-positive breast tumors with the XPO1 antagonist selinexor and the tamoxifen byproduct 4-OHT simultaneously rewires the cells’ metabolism to overcome endocrine resistance, University of Illinois researchers  found in a new study. The team, from left, graduate student Eylem Kulkoyluoglu-Cotul, food science and human nutrition professor Zeynep Madak-Erdogen, graduate student Brandi Patrice Smith and undergraduate student Kevin Duong. 

    Photo by Fred Zwicky

    Images

blog posts

  • Editor’s notes: To reach Zeynep Madak-Erdogan, call 217-300-9063; email zmadake2@illinois.edu

    The study “Combined targeting of estrogen receptor alpha and XPO1 prevent Akt activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance” is available online or from the News Bureau

    DOI: 10.3390/cancers11040479